APTN-101
EGFRvIII-positive malignant gliomas / brain tumors
Pre-clinicalActive
Key Facts
Indication
EGFRvIII-positive malignant gliomas / brain tumors
Phase
Pre-clinical
Status
Active
Company
About Adaptin Bio
Adaptin Bio is a private, preclinical-stage biotech developing a novel 'hitchhiking' drug delivery platform called BRiTE to transport therapeutics across biological barriers like the blood-brain barrier. Its lead program targets EGFRvIII-positive gliomas, addressing a major unmet need in oncology. Founded in 2021 and led by a team with prior exit experience, the company is positioning its platform to enable targeted therapies for CNS, autoimmune, and cardiovascular diseases.
View full company profile